Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 10
Submit an article Journal homepage
976
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Robust prognostic value of histologic transformation in patients with early progression of follicular lymphoma

Takafumi Shichijoa Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, JapanCorrespondence[email protected]
View further author information
,
Hiro Tatetsua Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, JapanCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0001-8131-3401View further author information
ORCID Icon,
Kisato Nosakaa Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, JapanView further author information
,
Yusuke Higuchia Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, JapanView further author information
,
Yoshitaka Kikukawab Department of Hematology and Oncology, Kumamoto City Hospital, Kumamoto, JapanView further author information
,
Kosuke Toyodaa Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, JapanORCID Iconhttps://orcid.org/0000-0001-8125-4528View further author information
ORCID Icon,
Shinya Shiraishic Department of Diagnostic Radiology, Kumamoto University Hospital, Kumamoto, JapanView further author information
,
Jun-ichirou Yasunagaa Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, JapanView further author information
&
Masao Matsuokaa Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, JapanView further author information
 show all
Pages 1706-1710 | Received 15 Mar 2023, Accepted 06 Jun 2023, Published online: 30 Jun 2023

References

  • Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144–152. doi: 10.1200/JCO.18.00400.
  • Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33(23):2516–2522. doi: 10.1200/JCO.2014.59.7534.
  • Shi Q, Flowers CR, Hiddemann W, et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J Clin Oncol. 2017;35(5):552–560. doi: 10.1200/JCO.2016.70.8651.
  • Dixon JG, Dimier N, Nielsen T, et al. End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma. Br J Haematol. 2022;198(2):333–337. doi: 10.1111/bjh.18217.
  • Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684–1693. doi: 10.1182/blood.2020010263.
  • Magnano L, Alonso-Alvarez S, Alcoceba M, et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019;185(3):480–491. doi: 10.1111/bjh.15805.
  • Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (gallium): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530–1542. doi: 10.1016/S1470-2045(18)30618-1.
  • Sarkozy C, Trneny M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575–2582. doi: 10.1200/JCO.2015.65.7163.
  • Shichijo T, Maruyama D, Yamauchi N, et al. Transformation scoring system (TSS): a new assessment index for clinical transformation of follicular lymphoma. Cancer Med. 2020;9(23):8864–8874. doi: 10.1002/cam4.3501.
  • Federico M, Caballero Barrigón MD, Marcheselli L, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5(8):e359-67–e367. doi: 10.1016/S2352-3026(18)30090-5.
  • Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi: 10.1200/JCO.2013.54.8800.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi: 10.1200/JCO.2006.09.2403.
  • Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi: 10.1038/bmt.2012.244.
  • Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the gallium study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202–1208. doi: 10.3324/haematol.2018.209015.
  • Muntañola A, Mozas P, Mercadal S, et al. Early progression in follicular lymphoma in the absence of histological transformation or high-risk follicular lymphoma international prognostic index still has a favourable outcome. Br J Haematol. 2023;200(3):306–314. doi: 10.1111/bjh.18522.
  • Batlevi CL, Sha F, Alperovich A, et al. Positron-emission tomographye-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer. 2020;126:78–90. doi: 10.1016/j.ejca.2019.12.006.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.